Effects of Emodin, a Plant-Derived Anthraquinone, on TGFβ1-Induced Cardiac Fibroblast Activation and Function
Abstract
Cardiac fibrosis accompanies a number of pathological conditions and results in altered myocardial structure, biomechanical properties and function. The signaling networks leading to fibrosis are complex, contributing to the general lack of progress in identifying effective therapeutic approaches to prevent or reverse this condition. Several studies have shown protective effects of emodin, a plant-derived anthraquinone, in animal models of fibrosis. A number of questions remain regarding the mechanisms whereby emodin impacts fibrosis. TGF-{beta}1 is a potent stimulus of fibrosis and fibroblast activation. In the present study, experiments were performed to evaluate the effects of emodin on activation and function of cardiac fibroblasts following treatment with TGF-{beta}1. We demonstrate that emodin attenuates TGF-{beta}1-induced fibroblast activation and collagen accumulation in vitro. Emodin also inhibits activation of several canonical (SMAD2/3) and non-canonical (Erk1/2) TGF-{beta} signaling pathways, while activating the p38 pathway. These results suggest that emodin may provide an effective therapeutic agent for fibrosis that functions via specific TGF-{beta} signaling pathways.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models
Milena Paw, Lukas Minder, … Gabriela Kania·bioRxiv·Aug 21, 2026
- Repurposing Nintedanib for Pathological Cardiac Remodeling and Dysfunction
P. Umbarkar, A. P. Singh, … H. Lal·Pharmacological ResearchPeer-reviewed·Jul 1, 2021
- Lanifibranor (IVA-337) - a pan-PPAR agonist suppresses TGF-β1-induced cardiac fibrosis and rescues cardiomyocyte function
Milena Paw, Lukas Minder, … Gabriela Kania·bioRxiv·Aug 21, 2026
- Logic-based mechanistic machine learning on high-content images reveals how drugs differentially regulate cardiac fibroblasts
Anders R. Nelson, Steven L. M. Christiansen, … Jeffrey J. Saucerman·Proceedings of the National Academy of SciencesPeer-reviewed·Jan 24, 2024
- Cardiac fibroblast GSK-3α mediates adverse myocardial fibrosis via IL-11 and ERK pathway
Prachi Umbarkar, Sultan Tousif, … Hind Lal·bioRxiv·Feb 2, 2021
- TNAP limits TGF-β-dependent cardiac and skeletal muscle fibrosis by inactivating SMAD2/3 transcription factors
G. Cossu, F. Galli, … E. Cartwright·bioRxiv·May 30, 2019